Page last updated: 2024-08-21

hydrazine and Myelodysplastic Syndromes

hydrazine has been researched along with Myelodysplastic Syndromes in 47 studies

Research

Studies (47)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (12.77)29.6817
2010's27 (57.45)24.3611
2020's14 (29.79)2.80

Authors

AuthorsStudies
Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M1
Ding, K; Duan, L; Fu, R; Guo, Y; Liu, Z; Shen, H1
Biemond, BJ; Boersma, RS; Chalandon, Y; de Weerdt, O; Deeren, D; Efthymiou, A; Fehr, M; Graux, C; Gregor, M; Heim, D; Janssen, JJWM; Jongen-Lavrencic, M; Klein, SK; Legdeur, MCJC; Löwenberg, B; Manz, M; Ossenkoppele, GJ; Pabst, T; Sinnige, HAM; Spertini, O; Stüssi, G; Tick, LW; van der Poel, MWM; van Norden, Y; van Obbergh, F; van Sluis, G; Westerweel, PE1
Boucher, R; Bowen, D; Cargo, C; Coulthard, HC; Culligan, D; Dennis, M; Jackson, A; Metzner, M; Moore, R; O'Sullivan, J; Raghavan, M; Sternberg, A; Vyas, P1
Grosicki, S; Lawniczek, T; Mittelman, M; Platzbecker, U; Selleslag, D; Zhu, Z1
Kulasekararaj, AG; Trikha, R1
Patel, BJ; Sekeres, MA1
Criscuolo, M; Cupelli, E; D'Alò, F; De Stefano, V; Fabiani, E; Falconi, G; Fianchi, L; Hohaus, S; Pagano, L; Zangrilli, I1
Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Sallman, D; Zhang, L1
Artz, AS; Bishop, M; Cooperrider, JH; Fulton, N; Kosuri, S; Larson, RA; Liu, H; Stock, W1
Babushok, DV; Sun, L1
Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J1
Albitar, M; Barranta, E; Calvo, KR; Dunbar, CE; Feng, X; Giudice, V; Groarke, E; Gutierrez-Rodrigues, F; Kajigaya, S; Lotter, J; Olnes, MJ; Parikh, AR; Patel, BA; Scheinberg, P; Shalhoub, R; Townsley, DM; Vicente, A; Weinstein, B; Winkler, T; Wu, CO; Young, NS1
Ades, PL; Al Jijakli, A; Azerad, MA; Berceanu, A; Beyne-Rauzy, O; Broner, J; Cherait, A; Cluzeau, T; Comont, T; Cony-Makhoul, P; Dimicoli, S; Fenaux, P; Gaudin, C; Giraud, JT; Gruson, B; Guerveno, C; Guillaume, T; Gyan, E; Jachiet, V; Laribi, K; Le Clech, L; Meunier, M; Sanhes, L; Santana, C; Slama, B; Torregrosa, J1
Altrock, E; Boch, T; Danner, J; Darwich, A; Flach, J; Haselmann, V; Hofmann, WK; Jann, JC; Jawhar, A; Jawhar, M; Knaflic, A; Marx, A; Mehralivand, A; Metzgeroth, G; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Palme, I; Riabov, V; Schmitt, N; Steiner, L; Streuer, A; Uhlig, S; Weimer, N; Weis, CA; Xu, Q1
Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N1
Afanasyev, B; Anagnostopoulos, A; Brenner, B; Denzlinger, C; Garcia-Delgado, R; Grosicki, S; Mittelman, M; Nagler, A; Platzbecker, U; Portella, MSO; Rossi, G; Selleslag, D; Wong, RSM; Zhu, Z1
Shastri, A; Verma, AK1
Buckstein, R1
Alvarado, Y; Bodden, K; Borthakur, G; Bueso-Ramos, C; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Kadia, TM; Khoury, J; Konopleva, M; Pemmaraju, N; Swaminathan, M; Yearby, B1
Caillon, H; Chevallier, P; Dejoie, T; Garnier, A; Guillaume, T; Lebourgeois, A; Peterlin, P; Ropert-Bouchet, M1
Afanasyev, B; Bonifazi, F; Bosman, P; Bruno, B; Cortelezzi, A; de Latour, RP; Dreger, P; Drénou, B; Drexler, B; Dufour, C; Ecsedi, M; Eikema, DJ; Garnier, A; Giammarco, S; Halkes, CJM; Knol-Bout, C; Lanino, E; Lengline, É; Ljungman, P; Maschan, A; Onofrillo, D; Passweg, J; Patriarca, A; Pioltelli, P; Pulanic, D; Risitano, AM; Rovó, A; Serventi-Seiwerth, R; Tournilhac, O1
Barcellini, W; Cassin, R; Fattizzo, B; Levati, G1
Pathak, S; Roth, M; Steidl, U; Verma, A1
Gauchan, D; Gedeon, D; Maroules, M; Shaaban, H1
Álvarez Román, MT; Arias-Salgado, EG; Butta, NV; de Paz, R; Fernández Bello, I; Jiménez Yuste, V; Martín Salces, M1
Bhagat, T; Braunschweig, I; Roth, M; Schinke, C; Steidl, U; Tamari, R; Verma, A; Will, B1
Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T1
Höchsmann, B; Körper, S; Schrezenmeier, H1
Locatelli, F; Merli, P; Palumbo, G; Strocchio, L; Vinti, L1
Kambhampati, S; Li, W; Morrone, K; Steidl, U; Verma, A; Will, B1
Abboud, C; Araujo, S; Bennett, J; Chan, G; Chen, CY; Cheng, G; Chiou, TJ; Dougherty, S; Feigert, J; Giagounidis, A; Gorin, NC; Götze, K; Greenberg, P; Jang, JH; Johnson, B; Kambhampati, S; Kamel, YM; Kim, YJ; Lee, JH; Lyons, R; Mannino, F; Platzbecker, U; Ruggeri, M; Santini, V; Stone, N; Verma, A; Wong, RS; Yeh, SP1
Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Ramadan, H; Zhang, L1
Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J1
Choy, KW; Doery, JC; Wijeratne, N1
Alati, C; Avanzini, P; Balleari, E; Bocchia, M; Bova, I; Buccisano, F; Carluccio, P; Cortelezzi, A; Cufari, P; D'Errigo, MG; Fenaux, P; Germing, U; Impera, S; Kulasekararaj, A; Latagliata, R; Liberati, AM; Mancini, S; Molteni, A; Morabito, F; Niscola, P; Oliva, EN; Palumbo, GA; Poloni, A; Salutari, P; Salvi, F; Sanpaolo, G; Santacaterina, I; Santini, V; Spiriti, MA; Stamatoullas, A; Voso, MT; Zini, G1
Komrokji, RS1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A1
Godeau, B1
Aivado, MA; Bruns, I; Erickson-Miller, CL; Kawahara, M; Luciano, JP; Parekh, S; Steidl, U; Verma, A; Will, B1
Sekeres, MA1
Leitch, HA; Vickars, LM1
Carraway, HE; Gore, SD; Loaiza-Bonilla, A1
Steensma, DP2
Kalpadakis, C; Kozana, A; Mavroudi, I; Papadaki, HA; Pavlaki, K; Pontikoglou, C; Psyllaki, M; Pyrovolaki, K1
Andreeff, M; Beran, M; Cahill, A; Clairmont, C; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Jeha, S; Kantarjian, H; Koller, C; Sznol, M; Thomas, D; Verstovsek, S1

Reviews

13 review(s) available for hydrazine and Myelodysplastic Syndromes

ArticleYear
Lowering the boom on lower-risk myelodysplastic syndromes.
    Hematology. American Society of Hematology. Education Program, 2019, 12-06, Volume: 2019, Issue:1

    Topics: Activin Receptors, Type II; Aged; Antilymphocyte Serum; Benzoates; Bone Marrow Cells; Female; Hematinics; Humans; Hydrazines; Immunoglobulin Fc Fragments; Lenalidomide; Mutation; Myelodysplastic Syndromes; Pyrazoles; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia

2019
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    The Cochrane database of systematic reviews, 2017, 09-30, Volume: 9

    Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin

2017
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
    Drugs, 2019, Volume: 79, Issue:12

    Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunomodulation; Immunosuppression Therapy; Megakaryocytes; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin

2019
Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; Benzoates; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Hematologic Diseases; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin; Thrombocytopenia

2013
[Aplastic anemia].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:49

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; DNA Mutational Analysis; Drug Therapy, Combination; Early Medical Intervention; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Randomized Controlled Trials as Topic; Shelterin Complex; Telomerase; Telomere-Binding Proteins; Transplantation Conditioning

2014
Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:14

    Topics: Anemia, Aplastic; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Hepatitis, Chronic; Humans; Hydrazines; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis

2015
Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
    Leukemia, 2016, Volume: 30, Issue:3

    Topics: Antineoplastic Agents; Benzoates; Blood Platelets; Cell Differentiation; Gene Expression Regulation, Neoplastic; Hemorrhage; Humans; Hydrazines; Megakaryocytes; Myelodysplastic Syndromes; Platelet Transfusion; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombocytopenia; Thrombopoietin

2016
[Novel medical treatment modalities in hematology].
    Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

    Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008
Treatment of MDS: something old, something new, something borrowed...
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin

2009
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Aged; Anemia; Benzoates; Blood Component Transfusion; Chelation Therapy; Combined Modality Therapy; Deferoxamine; Hematopoietic Cell Growth Factors; Humans; Hydrazines; Iron; Iron Chelating Agents; Iron Overload; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Off-Label Use; Phlebotomy; Practice Guidelines as Topic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin

2009
Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.
    Current opinion in hematology, 2010, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Benzoates; Enzyme Inhibitors; Humans; Hydrazines; Lenalidomide; Methyltransferases; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Thalidomide; Treatment Outcome

2010
Novel therapies for myelodysplastic syndromes.
    Hematology/oncology clinics of North America, 2010, Volume: 24, Issue:2

    Topics: Adenine Nucleotides; Aged; Alkylating Agents; Antimetabolites; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; DNA Repair; Drug Therapy, Combination; Drugs, Investigational; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Glutathione; Histone Deacetylase Inhibitors; Humans; Hydrazines; JNK Mitogen-Activated Protein Kinases; Myelodysplastic Syndromes; Quinolones; Sulfonamides; Therapies, Investigational

2010
Hematopoietic growth factors in myelodysplastic syndromes.
    Seminars in oncology, 2011, Volume: 38, Issue:5

    Topics: Benzoates; Colony-Stimulating Factors; Darbepoetin alfa; Drug-Related Side Effects and Adverse Reactions; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematinics; Humans; Hydrazines; Myelodysplastic Syndromes; Patient Selection; Polyethylene Glycols; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recombinant Proteins; Thrombopoietin

2011

Trials

12 trial(s) available for hydrazine and Myelodysplastic Syndromes

ArticleYear
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
    Leukemia, 2022, Volume: 36, Issue:9

    Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Triazoles

2022
Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).
    British journal of haematology, 2022, Volume: 199, Issue:2

    Topics: Azacitidine; Benzoates; Drug Combinations; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Treatment Outcome

2022
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:8

    Topics: Azacitidine; Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia; Treatment Outcome

2020
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
    Bone marrow transplantation, 2020, Volume: 55, Issue:11

    Topics: Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation Conditioning; Triazoles

2020
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
    The Lancet. Haematology, 2020, Volume: 7, Issue:8

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles

2020
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    The Lancet. Haematology, 2018, Volume: 5, Issue:1

    Topics: Aged; Benzoates; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Placebos; Pyrazoles; Safety; Thrombocytopenia

2018
A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Blood Platelets; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Prognosis; Pyrazoles; Treatment Outcome

2019
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
    European journal of haematology, 2014, Volume: 93, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Benzoates; Blood Platelets; Cell Cycle; Drug Synergism; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Hydrazines; Ischemic Attack, Transient; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Thrombocytopenia; Treatment Outcome; Venous Thrombosis

2014
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    The Lancet. Haematology, 2015, Volume: 2, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Benzoates; Double-Blind Method; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome

2015
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
    Clinical lymphoma, myeloma & leukemia, 2016, Volume: 16 Suppl

    Topics: Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Treatment Outcome

2016
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    The Lancet. Haematology, 2017, Volume: 4, Issue:3

    Topics: Aged; Aged, 80 and over; Benzoates; Disease Progression; Female; Humans; Hydrazines; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Single-Blind Method; Thrombocytopenia; Treatment Outcome

2017
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-01, Volume: 10, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Area Under Curve; Humans; Hydrazines; Leukemia, Myeloid; Metabolic Clearance Rate; Middle Aged; Myelodysplastic Syndromes; Nausea; Sulfonamides; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting

2004

Other Studies

22 other study(ies) available for hydrazine and Myelodysplastic Syndromes

ArticleYear
Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022, Volume: 70, Issue:4

    Topics: Apoptosis; Benzoates; Deferasirox; Humans; Hydrazines; Iron; Iron Chelating Agents; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia

2022
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
    Investigational new drugs, 2022, Volume: 40, Issue:4

    Topics: Azacitidine; Humans; Hydrazines; Myelodysplastic Syndromes; Neoplasms; Triazoles; Tumor Suppressor Protein p53

2022
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.
    Acta haematologica, 2023, Volume: 146, Issue:5

    Topics: Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukopenia; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome

2023
Eltrombopag in Lower-Risk Myelodysplastic Syndrome: Revival of Its Use in Thrombocytopenia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 10-01, Volume: 41, Issue:28

    Topics: Benzoates; Humans; Hydrazines; Myelodysplastic Syndromes; Thrombocytopenia

2023
    Platelets, 2021, Apr-03, Volume: 32, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Humans; Hydrazines; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thrombopoiesis

2021
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
    Blood, 2020, 07-02, Volume: 136, Issue:1

    Topics: Age of Onset; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Benzoates; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 7; Clonal Evolution; Clone Cells; Disease Progression; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Leukemia, Myeloid, Acute; Models, Biological; Monosomy; Mutation; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Pyrazoles; Selection, Genetic; Telomere Shortening

2020
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.
    Haematologica, 2020, 12-01, Volume: 105, Issue:12

    Topics: Benzoates; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles

2020
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    British journal of haematology, 2021, Volume: 194, Issue:2

    Topics: Aged; Aged, 80 and over; Benzoates; Blood Platelets; Female; France; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombocytopenia

2021
Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes.
    Leukemia, 2022, Volume: 36, Issue:1

    Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Benzoates; Cell Proliferation; Female; Humans; Hydrazines; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2022
Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.
    The Lancet. Haematology, 2018, Volume: 5, Issue:1

    Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk; Thrombocytopenia

2018
Eltrombopag use in higher risk myeloid cancers: fitting a square "pag" into a round hole?
    The Lancet. Haematology, 2019, Volume: 6, Issue:3

    Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk

2019
Eltrombopag induces major non-toxic hypersiderraemia.
    British journal of haematology, 2019, Volume: 186, Issue:2

    Topics: Aged; Allografts; Anemia, Hypochromic; Benzoates; Female; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Stem Cell Transplantation

2019
Use of eltrombopag in aplastic anemia in Europe.
    Annals of hematology, 2019, Volume: 98, Issue:6

    Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Drug Evaluation; Drug Utilization; Europe; Female; Follow-Up Studies; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Young Adult

2019
Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
    Annals of hematology, 2014, Volume: 93, Issue:10

    Topics: Aged, 80 and over; Benzoates; Bone Marrow; Erythrocyte Transfusion; Female; Hemorrhagic Disorders; Humans; Hydrazines; Myelodysplastic Syndromes; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia

2014
Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.
    British journal of clinical pharmacology, 2014, Volume: 78, Issue:3

    Topics: Aged; Benzoates; Case-Control Studies; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Tumor Necrosis Factor Ligand Superfamily Member 13

2014
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Clonal Evolution; Female; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thalidomide; Thrombopoiesis

2014
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
    International journal of hematology, 2017, Volume: 105, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin

2017
Eltrombopag: liver toxicity, kidney injury or assay interference?
    Pathology, 2016, Volume: 48, Issue:7

    Topics: Benzoates; Bilirubin; Chemical and Drug Induced Liver Injury; Creatinine; Drug Monitoring; Female; Humans; Hydrazines; Kidney; Kidney Function Tests; Liver Function Tests; Myelodysplastic Syndromes; Pyrazoles

2016
Use of eltrombopag for treatment of myelodysplastic syndromes.
    The Lancet. Haematology, 2017, Volume: 4, Issue:3

    Topics: Benzoates; Dose-Response Relationship, Drug; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Treatment Outcome

2017
[Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
    La Revue de medecine interne, 2009, Volume: 30, Issue:3

    Topics: Administration, Oral; Adult; Antiviral Agents; Benzoates; Carrier Proteins; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hydrazines; Immunoglobulins, Intravenous; Injections, Subcutaneous; Interferons; Myelodysplastic Syndromes; Placebos; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Ribavirin; Splenectomy; Thrombocytopenia; Thrombopoietin; Time Factors

2009
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
    Blood, 2009, Oct-29, Volume: 114, Issue:18

    Topics: Animals; Apoptosis; Benzoates; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Megakaryocytes; Mice; Mice, Inbred NOD; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Xenograft Model Antitumor Assays

2009
Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
    Leukemia research, 2011, Volume: 35, Issue:3

    Topics: Aged; Aged, 80 and over; Antigens, CD34; Apoptosis; Benzoates; Blotting, Western; Bone Marrow Cells; Cell Proliferation; Female; Humans; Hydrazines; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Risk Factors; Thrombopoiesis; Tumor Cells, Cultured

2011